Fierce Pharma

Rhythm's Imcivree scores 'transformative' FDA approval in brain damage-related obesity

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...
Seeking Alpha

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living ...
TMCnet

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...
Seeking Alpha

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses On Commercial Readiness For Acquired Hypothalamic Obesity Event Call (Transcript)

Good morning, everybody. Thank you for joining us today. I'm Dave Connolly, IR here at Rhythm Pharmaceuticals. Before we begin the speaking program, I'll just remind you that this event may include ...